Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival

Digestive Diseases and Sciences

Volumn 56, Issue 10, 2011, Pages 3086-3100

  Nanashima, Atsushi ^a   Taura, Naota ^a   Abo, Takafumi ^a   Ichikawa, Tatsuki ^a   Sakamoto, Ichiro ^a   Nagayasu, Takeshi ^a   Nakao, Kazuhiko ^a  

^a NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

AFP; Hepatocellular carcinoma; PIVKA II; Post curative treatment change; Survival

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATECTOMY; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN PRECURSORS; PROTHROMBIN; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 80054724610     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-1796-6     Document Type: Article

References (37)

1. H Nordenstedt DL White HB El-Serag 2010 The changing pattern of epidemiology in hepatocellular carcinoma Dig Liver Dis 42 S206 S214 20547305 10.1016/S1590-8658(10)60507-5
2. G Fattovich T Stroffolini I Zagni, et al. 2004 Hepatocellular carcinoma in cirrhosis: incidence and risk factors Gastroenterology 127 S35 S50 15508101 10.1053/j.gastro.2004.09.014 (Pubitemid 39423368)
3. M Nakano E Ando R Kuromatsu, et al. 2010 Recent progress in the management of hepatocellular carcinoma detected during a surveillance program in Japan Hepatol Res 40 989 996 20887334 10.1111/j.1872-034X.2010.00706.x 1:CAS:528:DC%2BC3cXhsFequ7fL
4. B Guiu A Minello V Cottet, et al. 2010 A 30-year, population-based study shows improved management and prognosis of hepatocellular carcinoma Clin Gastroenterol Hepatol 8 986 991 20713179 10.1016/j.cgh.2010.07.018
5. AM Di Bisceglie 2004 Issues in screening and surveillance for hepatocellular carcinoma Gastroenterology 127 S104 S107 15508072 10.1053/j.gastro.2004.09.022 (Pubitemid 39423376)
6. RW Pang JW Joh PJ Johnson, et al. 2008 Biology of hepatocellular carcinoma Ann Surg Oncol 15 962 971 18236113 10.1245/s10434-007-9730-z
7. H Okuda T Nakanishi K Takatsu, et al. 2002 Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone J Gastroenterol Hepatol 17 772 778 12121507 10.1046/j.1440-1746.2002.02806.x 1:CAS:528:DC%2BD38XntlSqtrc%3D (Pubitemid 34779738)
8. S Inoue A Nakao A Harada, et al. 1994 Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma Am J Gastroenterol 89 2222 2226 7526679 1:STN:280:DyaK2M%2Fmslynsw%3D%3D (Pubitemid 24363674)
9. T Nakagawa T Seki T Shiro, et al. 1999 Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma Int J Oncol 14 281 286 9917503 1:CAS:528: DyaK1MXhtFKjtbw%3D
10. M Tamano H Sugaya M Oguma, et al. 2002 Serum and tissue PIVKA-II expression reflect the biological malignant potential of small hepatocellular carcinoma Hepatol Res 22 261 269 11929711 10.1016/S1386-6346(01)00150-4 (Pubitemid 34498383)
11. F Yamashita M Tanaka S Satomura, et al. 1996 Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas Gastroenterology 111 996 1001 8831594 10.1016/S0016-5085(96)70067-7 1:STN:280:DyaK28vivVCqsw%3D%3D (Pubitemid 26327602)
12. N Kokudo M Makuuchi 2009 Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: The J-HCC guidelines J Gastroenterol 44 119 121 19148805 10.1007/s00535-008-2244-z
13. A Nanashima S Morino H Yamaguchi, et al. 2003 Modified CLIP using PIVKA-II for evaluating prognosis after hepatectomy for hepatocellular carcinoma Eur J Surg Oncol 29 735 742 14602492 10.1016/j.ejso.2003.08.007 1:STN:280:DC%2BD3srisVKhtA%3D%3D (Pubitemid 37483946)
14. A Nanashima Y Sumida S Tobinaga, et al. 2006 Postoperative changes in protein-induced vitamin K absence or antagonist II levels after hepatectomy in patients with hepatocellular carcinoma: Relationship to prognosis HPB (Oxford) 8 137 141 1:STN:280:DC%2BD1c7nsVSntA%3D%3D
15. S Iwadou K Nouso K Kuwaki, et al. 2010 Time-dependent analysis of predisposing factors for the recurrence of hepatocellular carcinoma Liver Int 30 1027 1032 20492506 10.1111/j.1478-3231.2010.02252.x 1:CAS:528: DC%2BC3cXhtVGksrzL
16. K Kishi T Sonomura K Mitsuzane, et al. 1992 Time courses of PIVKA-II and AFP levels after hepatic artery embolization and hepatic artery infusion against hepatocellular carcinoma: relation between the time course and tumor necrosis Radiat Med 10 189 195 1279748 1:STN:280:DyaK3s%2FmslWkug%3D%3D
17. D Nobuoka Y Kato N Gotohda, et al. 2010 Postoperative serum alpha-fetoprotein level is a useful predictor of recurrence after hepatectomy for hepatocellular carcinoma Oncol Rep 24 521 528 20596642 1:CAS:528: DC%2BC3cXhtVClsLjE
18. JA Marrero Z Feng Y Wang, et al. 2009 Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma Gastroenterology 137 110 118 19362088 10.1053/j.gastro.2009.04.005 1:CAS:528:DC%2BD1MXovFOgsbs%3D
19. Liver Cancer Study Group of Japan. Stage. In: Makuuchi M, ed. The general rules for the clinical and pathological study of primary liver cancer (in Japanese). 4th ed. Tokyo: Kanehara & Co. Ltd.; 2000:19.
20. M Donati G Brancato A Donati 2010 Clinical biomarkers in hepatocellular carcinoma (HCC) Front Biosci (Schol Ed) 2 571 577 10.2741/s86
21. G Malaguarnera M Giordano I Paladina, et al. 2010 Serum markers of hepatocellular carcinoma Dig Dis Sci 55 2744 2755 20339916 10.1007/s10620-010- 1184-7 1:CAS:528:DC%2BC3cXhtF2lurvP
22. K Yamamoto H Imamura Y Matsuyama, et al. 2009 Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy Ann Surg Oncol 16 2795 2804 19669841 10.1245/s10434-009-0618-y
23. A Nanashima Y Sumida T Abo, et al. 2006 Modified Japan Integrated Staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy J Gastroenterol 41 250 256 16699859 10.1007/s00535-005-1751-4
24. T Koh H Taniguchi H Katoh, et al. 2002 Are both PIVKA-II and alpha-fetoprotein necessary in follow-up management after hepatic resection for hepatocellular carcinoma? Hepatogastroenterology 49 1615 1618 12397748 1:CAS:528:DC%2BD38XosFehurk%3D (Pubitemid 35277339)
25. N Kanazumi S Takeda S Inoue, et al. 2000 PIVKA-II during perioperative period in patients with hepato-biliary-pancreatic diseases Hepatogastroenterology 47 1695 1699 11149034 1:STN:280:DC%2BD3M7itlWjtA%3D%3D
26. CS Wang CL Lin HC Lee, et al. 2005 Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma World J Gastroenterol 11 6115 6159 16273636 1:CAS:528:DC%2BD28XhsVentLs%3D
27. HS Kim JW Park JS Jang, et al. 2009 Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study J Clin Gastroenterol 43 482 488 19197197 10.1097/MCG.0b013e318182015a 1:CAS:528:DC%2BD1MXntFyqsLc%3D
28. C Ogawa M Kudo Y Minami, et al. 2008 Tumor markers after radiofrequency ablation therapy for hepatocellular carcinoma Hepatogastroenterology 55 1454 1457 18795710
29. A Taketomi K Sanefuji Y Soejima, et al. 2009 Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation Transplantation 87 531 537 19307789 10.1097/TP.0b013e3181943bee
30. LG Lu MD Zeng MB Wan, et al. 2003 Grading and staging of hepatic fibrosis, and its relationship with noninvasive diagnostic parameters World J Gastroenterol 9 2574 2578 14606100
31. M Abdel-Wahab TS El-Husseiny E El Hanafy, et al. 2010 Prognostic factors affecting survival and recurrence after hepatic resection for hepatocellular carcinoma in cirrhotic liver Langenbecks Arch Surg 395 625 632 20358380 10.1007/s00423-010-0643-0
32. J Strople G Lovell J Heubi 2009 Prevalence of subclinical vitamin K deficiency in cholestatic liver disease J Pediatr Gastroenterol Nutr 49 78 84 19502999 10.1097/MPG.0b013e31819a61ff 1:CAS:528:DC%2BD1MXptFCrsLs%3D
33. CT Lin KF Hsu TW Chen, et al. 2010 Comparing hepatic resection and transarterial chemoembolization for Barcelona clinic liver cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice? World J Surg 34 2155 2161 20407768 10.1007/s00268-010-0598-x
34. D Nobuoka Y Kato N Gotohda, et al. 2010 Postoperative serum alpha-fetoprotein level is a useful predictor of recurrence after hepatectomy for hepatocellular carcinoma Oncol Rep 24 521 528 20596642 1:CAS:528: DC%2BC3cXhtVClsLjE
35. Y Tamura M Igarashi T Suda, et al. 2010 Fucosylated fraction of alpha-fetoprotein as a predictor of prognosis in patients with hepatocellular carcinoma after curative treatment Dig Dis Sci 55 2095 2101 19731025 10.1007/s10620-009-0954-6 1:CAS:528:DC%2BC3cXnsF2ju70%3D
36. K Yamamoto H Imamura Y Matsuyama, et al. 2010 AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC J Gastroenterol 45 1272 1282 20625772 10.1007/s00535-010-0278-5 1:CAS:528:DC%2BC3cXhsFKqu73J
37. P Abrams JW Marsh 2010 Current approach to hepatocellular carcinoma Surg Clin North Am 90 803 816 20637949 10.1016/j.suc.2010.04.010